CD8A and melanoma: Current therapy has predominantly shifted to immune checkpoint blockers (ipilimumab, nivolumab, pembrolizumab), which release the natural brakes on the immune system and allow CD8+ T cells to recognize and eliminate melanoma cells [6,7,8].